---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-041132"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:48:06.306516+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ionis enters gene editing collaboration with Metagenomi; raises FY2022 expense guidance

## Summary
- Upfront $80M payment to Metagenomi for exclusive worldwide rights to develop gene editing medicines for up to 8 targets.
- Collaboration covers 4 initial targets selected by Ionis, plus 4 more upon milestones; Metagenomi has co-development option.
- FY2022 guidance: OpEx raised to $900-925M (from $825-850M); net loss on non-GAAP now <$350M (from <$275M); revenue >$575M unchanged.
- Cash, cash equivalents and short-term investments ~$2.0B, unchanged.
- Each party agreed to exclusivity on selected targets for specified periods under the agreement.

## SEC filing metadata
- accession: 0001140361-22-041132
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/0001140361-22-041132-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/brhc10044032_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-041132
- JSON: https://secwatch.observer/filing/0001140361-22-041132.json
- Plain text: https://secwatch.observer/filing/0001140361-22-041132.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC reported full year 2022 results: revenue >$575 million, net income <$350 million. Guidance raised.
  - Period: full year 2022
  - Revenue: >$575 million
  - Net income: <$350 million
  - Guidance: raised
  - Result: guidance update
  source text: Item 2.02 Results of Operations and Financial Condition. In connection with the Company’s entry into the Agreement, the Company increased its full year 2022 guidance for operating expenses and net loss, on a non-GAAP basis, to incorporate the upfront payment to Metagenomi, all as reflected in the table below. Full Year 2022 Guidance Revised Guidance Previous As of Q3 2022 Revenue >$575 million >$575 million Operating expenses on a non-GAAP basis $900-$925 million $825-$850 million Net loss on a non-GAAP basis <$350 million <$275 million Cash, cash equivalents and short-term investments ~2.0 billion ~$2.0 billion
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/0001140361-22-041132-index.htm
- Material Agreements
  IONIS PHARMACEUTICALS INC entered into Collaboration and License Agreement with Metagenomi, Inc. valued at $80 million upfront fee, plus target selection fees, development/regulatory/sales milestones, and ro (effective 2022-11-10).
  - Action: entry
  - Agreement: license
  - Counterparty: Metagenomi, Inc.
  - Value: $80 million upfront fee, plus target selection fees, development/regulatory/sales milestones, and ro
  - Effective: 2022-11-10
  source text: On November 10, 2022, Ionis Pharmaceuticals, Inc. (the “ Company ”) entered into a collaboration and license agreement (the “ Agreement ”) with Metagenomi, Inc. (“ Metagenomi ”) to research, develop and commercialize investigational medicines for up to eight potential genetic targets using gene editing technologies.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036122041132/0001140361-22-041132-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.